Diurnal Group Plc Infacort® – On track to market

Hardman & Co ReportDiurnal Group Plc (LON:DNL) is a clinical stage specialty pharmaceutical company focused on diseases of the endocrine system. It has two lead candidates – Infacort that completed its Phase III in Dec 2016 and Chronocort, currently in Phase III trials – targeted at rare diseases with unmet medical need, and is aiming to build a long-term ‘Adrenal Franchise’. The completed Phase III trial confirmed that Infacort is well tolerated, achieved its primary endpoint and received the support of the parents and carers. Infacort will represent the first licenced cortisol replacement therapy for children and is on track to achieve market authorisation in late 2017 and sales in early 2018.

 
Strategy: Diurnal’s strategic goal is to create a valuable ‘Adrenal Franchise’ that can treat patients with chronic cortisol deficiency diseases from birth through to old age. Once Infacort and Chronocort are established in Europe and the US, the long-term vision is to expand the product offering to other conditions.

Phase III clinical trial: Results from the European Phase III study on children from new-borns to six years of age, showed Infacort to be a paediatric compliant and well tolerated cortisol replacement treatment. No adverse effect was detected and Infacort received support from 95% of parents and carers.

Route to market: These Phase III results represent an important step towards marketing approval in Europe, expected in late 2017. They will support a future study to be performed in the US. Infacort would be the first licenced cortisol treatment in children, hence providing a solution to an unmet medical need.

Risks: As with all drug development companies, there is a risk that products will fail in clinical trials. Diurnal is much lower risk given that its products are formulation variants of well-established drugs. Moreover, with the PUMA dossier already validated by the EMA, Diurnal is in the market authorisation process.

Investment summary: Diurnal Group Plc is focusing on diseases of the endocrine system. Infacort, a cortisol replacement designed for children and babies, is the first product Diurnal will bring to the market. It will be followed by Chronocort for adults. The cortisol replacement market is for conditions that need life-long treatments, with a potential value of $3.5bn.

There does not appear to be a profile here yet (if this your your plc please get in touch)
Facebook
Twitter
LinkedIn
Hardman & Co

More articles like this

ZoteFoams

Zotefoams achieves record profit, significant investment in ReZorce®

Zotefoams plc (LON:ZTF), a world leader in cellular material technology, has announced its unaudited preliminary results for the year ended 31 December 2023. “Record profit alongside significant investment in our ReZorce® recyclable packaging solution.” Financial Highlights   Foams4

Team plc

The impact of ‘Carbon Cowboys’ on global climate inequities

In the vast expanse of the climate change frontier, there roam “Carbon Cowboys.” These aren’t the traditional Wild West cowboys, but modern entities, often corporations, quangos, assemblies and governments, who wield immense power over carbon emissions.

Quadrise plc

The potential of Biofuels for reducing GHG emissions

As the shipping industry grapples with its significant contribution to global greenhouse gas emissions (GHG), accounting for approximately 3%, alongside exacerbating water and underwater noise pollution, sustainability has emerged as a critical priority. Achieving sustainability in

Biome Technologies

Bioplastics: A sustainable alternative to conventional packaging

In recent years, the global push towards sustainability has significantly influenced various sectors, with the packaging industry standing at the forefront of this transformative wave. Amidst growing environmental concerns, such as plastic pollution and greenhouse gas

Fidelity Japan Trust

Nikkei 225 index climbs in Japan as Yen weakens

In Japan, the Nikkei 225 index climbed the most in a month and the yen traded weaker against the dollar, amid signs markets have priced in the potential for an interest-rate increase. “Japanese stocks are rising,